An Open Label Long Term Follow up Study for Patients With Melanoma Who Were Previously Enrolled in the Phase I Study IMM-101-001
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Mar 2017
At a glance
- Drugs IMM 101 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Sponsors Immodulon Therapeutics
- 04 Mar 2017 Planned End Date changed from 1 Feb 2016 to 1 Mar 2019.
- 04 Mar 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Dec 2018.
- 05 May 2015 New trial record